Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have received a consensus rating of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $76.50.

Several equities research analysts have issued reports on the company. HC Wainwright dropped their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating for the company. Finally, Citigroup assumed coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. ANTIPODES PARTNERS Ltd lifted its stake in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI lifted its stake in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after acquiring an additional 953 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Up 4.1%

NASDAQ:GPCR traded up $0.89 during trading hours on Friday, hitting $22.72. 1,392,477 shares of the company's stock traded hands, compared to its average volume of 858,549. The firm has a market cap of $1.30 billion, a P/E ratio of -30.70 and a beta of -1.87. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $53.45. The business's fifty day simple moving average is $22.18 and its two-hundred day simple moving average is $24.86.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, analysts expect that Structure Therapeutics will post -0.82 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.